We are live on ! Find out more
SLDB icon

Solid Biosciences

130 hedge funds and large institutions have $459M invested in Solid Biosciences in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 47 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

23,267% more call options, than puts

Call options by funds: $3.5M | Put options by funds: $15K

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

2% more funds holding

Funds holding: 127130 (+3)

0.05% less ownership

Funds ownership: 104.5%104.45% (-0.05%)

9% less capital invested

Capital invested by funds: $502M → $459M (-$43.1M)

23% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 47

Holders
130
Holders Change
+3
Holders Change %
+2.36%
% of All Funds
1.58%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
14
Increased
36
Reduced
47
Closed
11
Calls
$3.5M
Puts
$15K
Net Calls
+$3.49M
Net Calls Change
-$568K

SLDB Hedge Fund Activity: Q4 2025 in Review

130 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q4 2025, worth a combined $459M — down 8.6% from $502M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SLDB positions and 11 closed out — a net gain of 3 holders — while 36 added to existing stakes and 47 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $15.4M. The largest seller was Adage Capital Partners, cutting an estimated $14.1M.

  • 130 institutional investors held Solid Biosciences (SLDB) as of Q4 2025, up from 127 in Q3 2025.
  • Funds reported $459M of Solid Biosciences stock for Q4 2025, down 8.6% quarter-over-quarter.
  • 14 funds opened new Solid Biosciences positions in Q4 2025 and 11 closed out, a net change of +3 holders.
  • The largest Solid Biosciences buyer in Q4 2025 was Vestal Point Capital, an estimated $15.4M added.
  • The largest Solid Biosciences seller in Q4 2025 was Adage Capital Partners, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2025.